FDA Panel Rejects Intellipharmaceutics' Opioid For Missing Data, Blue Dye Safety Concern

Panel members question why company pursued filing for its oxycodone ER given lack of data; agrees with FDA that blue Gatorade consumption does not show safety of dye excipient used to deter abuse.